assessing metabolic tumor volume as a prognostic marker before car-t therapy for dlbcl
Published 8 months ago • 78 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
2:16
autosct vs car-t for patients with relapsed lbcl in pr: the role of total metabolic tumor volume
-
3:10
universal car-t therapy for t-all
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:28
assessment of car-t and tcr adverse events
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
4:34
development and evaluation of a novel car-t cell therapy against calr mutant neoplasms
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy
-
1:38
challenges of car-t therapy in the real-world setting
-
1:16
hurdles to car-t therapy for mds & aml: t-cell fitness & lack of a uniform target antigen
-
3:05
car-t therapy in r/r dlbcl
-
4:10
car t-cell therapy for all
-
1:44
bispecific antibodies vs car-t cells in dlbcl: the benefit of car-t therapy
-
7:36
star t-cell therapy for r/r b-cell all
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:02
the use of car-t cell products in a real-world setting
-
1:15
car t-cells in hematological malignancies
-
2:49
identifying novel antigens for tcr t-cell therapy
-
2:44
do biomarkers exist for predicting response to car t-cell therapy?
-
0:37
hot topics in car t-cell therapy for all